Abstract:OBJECTIVE:To explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.METHODS:Two-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.RESULTS:In group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).CONCLUSION:Patients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.

Clinical Research of Intravenation of Hepatocyte Growth Promoting Factors on Hepatitis Gravis

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Efficiency of Double Plasma Molecular Absorption System on the Acute Severe Cholestatic Hepatitis.

Pathologic Characteristics of Immunologic Injury in Primary Cultured Rat Hepatocytes and Protective Effect of Glycyrrhizin in Vitro

Promoting Hepatic Growth Factor in the Treatment of Heavy Type Hepatitis and Severe Chronic Hepatitis: a Multicenter Clinical Study.

[Clinical Research of Plasma Exchange with Continuous Veno-Venous Hemofiltration in Treating Mid- and Late-Stage Chronic Severe Viral Hepatitis B Patients].

Effects of Hemoperfusion Adsorption And/or Plasma Exchange in Treatment of Severe Viral Hepatitis: A Comparative Study

Effect of Artificial Liver Support System on Patients with Severe Viral Hepatitis: A Study of Four Hundred Cases

Clinical Evaluation of Treatment with Artificial Liver Support System in Chronic Fulminant Viral Hepatitis

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

Supporting Effects of Porcine Cell-Based Hybrid Bioartificial Liver on Patients with Gravis Hepatitis

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Clinical and pathologic study on hepatic veno-occlusive disease

The Clinical Effect of Hybrid Bioartificial Liver on Acute Hepatic Failure with Gravis Hepatitis

The Clinical Studies on the Safety and Efficacy of Glutathione for Injection for Patients with Chronic Viral and Toxic Hepatitis

Effect of L-ornithine L-aspartate Granules in Treating Chronic Liver Disease in Patients with High-Level Serum Gamma-Glutamyltransferase

Retrospective Analysis of the Clinical Efficacy of N-Acetylcysteine in the Treatment of Hepatitis B Virus Related Acute-on-Chronic Liver Failure

Clinical Observation of Gankang Granules in Treating Chronic Hepatitis B

Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial